MIPR NUMBER 93M3506

TITLE: Interphase Cytogenetics in Breast Tumors P53 Gene Alterations

PRINCIPAL INVESTIGATOR: Isabell A. Sesterhenn, M.D.

CONTRACTING ORGANIZATION: Armed Forces Institute of Pathology
Washington, DC 20306-6000

REPORT DATE: October 1993

TYPE OF REPORT: Midterm

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
REPORT DOCUMENTATION PAGE

4. TITLE AND SUBTITLE
Interphase Cytogenetics in Breast Tumors P53 Gene Alterations

8. AUTHOR(S)
Sesterhenn, Isabell A, M.D.

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)
Armed Forces Institute of Pathology
Washington, DC 20306-6000

11. SUPPLEMENTARY NOTES
Approved for public release; distribution unlimited

13. ABSTRACT (Maximum 200 words)
PURPOSE: To compare numerical chromosome aberrations and p53 gene alterations in 250 node-negative breast cancers to 250 non-positive breast cancers and their survival. SCOPE: Interphase cytogenetics will be performed in paraffin sections utilizing biotinylated probes specific for centromeric regions of chromosomes 1, 8, 11, 13, 17, 18, and X. Chromosome profiles based on 300 tumor cells will be generated for each patient. Serial sections of the same paraffin blocks will be utilized to assess p53 alterations immunohistochemically. If present, further amplification and sequencing of p53 gene will be done utilizing PCR denaturing gel gradient electrophoresis and coupled amplification and sequencing protocols.

MAJOR FINDINGS: Preliminary analysis showed there was a statistically significant increase in the copy numbers of chromosome 1 with nuclear grade. Similarly, increasing numbers of chromosome 18 were observed with increase in nuclear grade. However, there was no significant increase in the copy numbers of chromosomes 8, 11, 13/21, 17 and X when correlated with nuclear grade. All of them showed extra copies in nuclear grade I, II, and III tumors. Comparison of copy numbers of the different chromosomes in tumor to normal epithelial cells showed a gain for chromosomes 8, 11, 13/21, 17, and X. However, in individual cases, loss of chromosome 17 and X chromosome was encountered.

Breast Cancer

17. SECURITY CLASSIFICATION OF REPORT
Unclassified

18. SECURITY CLASSIFICATION OF THIS PAGE
Unclassified

19. SECURITY CLASSIFICATION OF ABSTRACT
Unclassified

20. LIMITATION OF ABSTRACT
Unlimited

NSN 7540-01-280-5500
Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

2.5. For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

[Signature] 13-Mar-97
PI - Signature  Date
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cover</td>
<td>1</td>
</tr>
<tr>
<td>SF 298</td>
<td>2</td>
</tr>
<tr>
<td>Foreword</td>
<td>3</td>
</tr>
<tr>
<td>Table of Contents</td>
<td>4</td>
</tr>
<tr>
<td>Purpose</td>
<td>5</td>
</tr>
<tr>
<td>Scope</td>
<td>5</td>
</tr>
<tr>
<td>Major Findings</td>
<td>5</td>
</tr>
</tbody>
</table>
MID-TERM REPORT - 93MM3506

TITLE OF PROPOSAL: Interphase Cytogenetics in Breast Tumors p53 Gene Alterations.

PRINCIPAL INVESTIGATOR: Isabell A. Sesterhenn, M.D.

Ref.: DD Form 448, Amendment received [dated 12/10/96] extending proposal period until 30 JUNE 1998.

PURPOSE: To compare numerical chromosome aberrations and p53 gene alterations in 250 node-negative breast cancers to 250 non-positive breast cancers and their survival. Although conventional cytogenetic analysis has been successful only in about 50 breast cancers, it has been helpful in identification of subtypes of ductal carcinomas. Since cytogenetic equivalents for gene amplification are net gain of chromosomal material and for loss of heterozygosity are net loss of chromosomal material or structural aberrations, we believe that interphase cytogenetics may be helpful in subclassification of ductal carcinomas. P53 gene alterations may prove to be an early event in breast cancer progression.

SCOPE: Interphase cytogenetics will be performed in paraffin sections utilizing biotinylated probes specific for centromeric regions of chromosomes 1, 8, 11, 13, 17, 18, and X. Chromosome profiles based on 300 tumor cells will be generated for each patient. Serial sections of the same paraffin blocks will be utilized by Dr. O'Leary to assess p53 alterations immunohistochemically. If present, further amplification and sequencing of p53 gene will be done utilizing PCR denaturing gel gradient electrophoresis and coupled amplification and sequencing protocols. The data will be analyzed by the Kaplan-Meyer and Cox proportional hazards model, comparing the two groups of patients. Pathology Data Division is follow-up in progress.

MAJOR FINDINGS: Two hundred ninety-two cases have been completed. An additional 78 cases are close to completion. Pathology Data Division follow-up is in progress.

Preliminary analysis of 37 node-negative tumors, statistical analysis was performed. The Jonckheere-Terpstra test (Hollander & Wolfe, 1973) was used to determine if the chromosomal spot counts were identically distributed in each grade considered. In addition, the standardized Jonckheere-Terpstra test statistics allow one to determine the relationship between chromosomal spot counts and grade. Two-sided asymptotic p-values were determined. Integer values were used for each chromosomal spot count. The Jonckheere-Terpstra test was also used to compare normal tissue chromosomal spot counts to tumor chromosomal spot counts, with both tissues coming from the same biopsy.

Comparison of the chromosomal profiles to the tumor grade as determined by the Bloom and Richardson methods modified by Elston
did not show any correlation. However, if the tumors were grouped according to the nuclear grade, there was a statistically significant increase in the copy numbers of chromosome 1 with nuclear grade. Similarly, increasing numbers of chromosome 18 were observed with increase in nuclear grade. However, there was no significant increase in the copy numbers of chromosomes 8, 11, 13/21, 17 and X when correlated with nuclear grade. All of them showed extra copies in nuclear grade I, II, and III tumors. Comparison of copy numbers of the different chromosomes in tumor to normal epithelial cells showed a gain for chromosomes-8, 11, 13/21, 17, and X. However, in individual cases, loss of chromosome 17 and X chromosome was encountered.

p53 analysis is in progress.